MedPath

Oxytocin

Generic Name
Oxytocin
Brand Names
Pitocin
Drug Type
Biotech
CAS Number
50-56-6
Unique Ingredient Identifier
1JQS135EYN

Overview

Sir Henry H. Dale first identified oxytocin and its uterine contractile properties in 1906. Like all other neurohypophysial hormones, oxytocin is composed of nine amino acids with a disulfide bridge between the Cys 1 and 6 residues. In the mid-1950s, synthetic oxytocin was successfully synthesized by a biochemist named Vincent du Vigneaud; he was later recognized with a Nobel prize for his work. Oxytocin continues to be an important tool in modern obstetrics to induce labor when indicated and to manage postpartum hemorrhage. It is estimated that labor induction with oxytocin is used in almost 10% of deliveries globally. It should be noted that there are risks associated with oxytocin intervention during childbirth. Oxytocin should be used judiciously only when necessary and by experienced healthcare practitioners. Although most commonly linked to labor and delivery, oxytocin actually has broad peripheral and central effects. It plays an important role in pair bonding, social cognition and functioning, and even fear conditioning. Oxytocin also serves a role in metabolic homeostasis and cardiovascular regulation.

Indication

Administration of exogenous oxytocin is indicated in the antepartum period to initiate or improve uterine contractions for vaginal delivery in situations where there is fetal or maternal concern. For example, It may be used to induce labor in cases of Rh sensitization, maternal diabetes, preeclampsia at or near term, and when delivery is indicated due to prematurely ruptured membranes. Importantly, oxytocin is not approved or indicated for elective induction of labor. Oxytocin may be used to reinforce labor in select cases of uterine inertia and as adjunctive therapy in the management of incomplete or inevitable abortion. In the postpartum period, oxytocin may be used to induced contractions in the 3rd stage of labor and to control postpartum bleeding or hemorrhage.

Associated Conditions

  • Incomplete Abortion
  • Inevitable abortion
  • Postpartum Bleeding

Research Report

Published: Jul 14, 2025

Oxytocin (DB00107): A Comprehensive Monograph on its Pharmacological, Clinical, and Neuroscientific Profile

Executive Summary

Oxytocin is a cyclic nonapeptide hormone and neuromodulator with a dual identity that defines its clinical and investigational landscape. As a peripherally acting hormone, it is an indispensable and potent uterotonic agent, classified as a biotech drug and protein-based therapy. Its primary, FDA-approved clinical applications are in obstetrics, where it is used to induce or augment labor, manage inevitable or incomplete abortions, and, most critically, to control and prevent postpartum hemorrhage (PPH). The administration of oxytocin in this context is characterized by a narrow therapeutic index and significant risks, including uterine hyperstimulation, fetal distress, and maternal water intoxication. Consequently, its use demands strict adherence to clinical protocols, including administration via calibrated infusion pump and continuous maternal and fetal monitoring.

Centrally, oxytocin functions as a neurotransmitter within the brain, modulating a complex array of social and emotional behaviors. Often dubbed the "love hormone," its role is more accurately described as a facilitator of social salience, with effects that are highly dependent on individual and contextual factors. This central activity has spurred a vast field of research investigating its therapeutic potential for neuropsychiatric disorders characterized by social deficits, such as autism spectrum disorder (ASD), anxiety disorders, and depression. Despite decades of study, the evidence for these applications remains largely inconclusive and often contradictory. Clinical trials have been hampered by inconsistent findings, methodological challenges related to drug delivery to the brain, and a lack of standardized assays for measuring endogenous oxytocin.

Continue reading the full research report

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/07/08
Not Applicable
Not yet recruiting
2025/07/08
Not Applicable
Completed
2025/06/05
Not Applicable
Not yet recruiting
2025/05/13
Phase 2
Not yet recruiting
Insud Pharma
2025/04/27
Phase 2
Not yet recruiting
Zhejiang University
2025/04/16
Not Applicable
Recruiting
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
2025/03/25
Not Applicable
Recruiting
University Hospital, Gentofte, Copenhagen
2025/03/21
Not Applicable
Completed
2025/03/18
Phase 2
Recruiting
Central Institute of Mental Health, Mannheim
2025/02/05
Phase 2
Not yet recruiting
University Hospital, Basel, Switzerland

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Cantrell Drug Company
52533-105
INTRAVENOUS
2 [USP'U] in 100 mL
12/11/2014
Dr. Donna Restivo DC
62185-0059
ORAL
12 [hp_X] in 1 mL
5/23/2025
Par Pharmaceutical, Inc.
42023-130
INTRAVENOUS
10 [iU] in 1 mL
9/9/2020
Cantrell Drug Company
52533-233
INTRAVENOUS
20 [USP'U] in 500 mL
3/18/2016
Cantrell Drug Company
52533-056
INTRAVENOUS
30 [USP'U] in 500 mL
12/11/2014
West-Ward Pharmaceuticals Corp
0143-9742
INTRAMUSCULAR, INTRAVENOUS
10 [USP'U] in 1 mL
9/17/2018
Cantrell Drug Company
52533-048
INTRAVENOUS
10 [USP'U] in 1000 mL
12/11/2014
Hikma Pharmaceuticals USA Inc.
0641-6114
INTRAMUSCULAR, INTRAVENOUS
10 [USP'U] in 1 mL
9/17/2018
Cantrell Drug Company
52533-055
INTRAVENOUS
30 [USP'U] in 500 mL
12/24/2014
Cantrell Drug Company
52533-234
INTRAVENOUS
30 [USP'U] in 1000 mL
3/18/2016

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
SYNTOMETRINE INJECTION
SIN03588P
INJECTION
5 iu/ml
7/5/1989
SYNTOCINON INJECTION 10 iu/ml
Steriscience Sp. z o.o. (manufacture of Syntocinon 10 IU/ml), Steriscience Sp. z o.o. (manufacture of drug intermediate Oxytocin 200 IU/ml concentrate)
SIN02496P
INJECTION
10 iu/ml
3/14/1989
OXYTOCIN GRINDEKS SOLUTION FOR INJECTION AND INFUSION 10 IU/ML
SIN17068P
INJECTION, SOLUTION
10iu/mL
8/23/2024

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Oxytocin for Injection
深圳翰宇药业股份有限公司;甘肃成纪生物药业有限公司
国药准字H20059994
化学药品
冻干粉针剂
4/15/2020
Oxytocin for Injection
国药准字H20059993
化学药品
注射剂
3/17/2020
Oxytocin for Injection
国药准字H10930232
化学药品
注射剂
7/21/2020
Oxytocin for Injection
国药准字H10930233
化学药品
注射剂
7/21/2020
Oxytocin Injection
国药准字H31020862
化学药品
注射剂
3/27/2020
Oxytocin Injection
国药准字H20253395
化学药品
注射剂
2/20/2025
Oxytocin Injection
国药准字H62020713
化学药品
注射剂
11/17/2020
Oxytocin Injection
国药准字H51021983
化学药品
注射剂(注射液)
1/20/2021
Oxytocin Injection
国药准字H34020474
化学药品
注射剂
4/13/2020
Oxytocin Injection
国药准字H20233816
化学药品
注射剂
6/27/2023

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.